Current clinical and preclinical evidence of aberrant gamma oscillations in PD is summarized, underlying mechanisms including parvalbumin interneuron dysfunction, basal ganglia circuit imbalance, and impaired neurovascular coupling are discussed, and how current therapeutic approaches for PD modulate gamma activity and potentially influence clinical outcomes are summarized.
Parkinson's disease (PD) is increasingly recognized as a multisystem neurodegenerative disorder that extends far beyond its classical motor manifestations. Among its non-motor symptoms, sleep disturbances are among the most prevalent and disabling clinical features, affecting up to 80% of patients and often preceding t...
Hai-Cheng Huang, Peng E. Ruan, Yi-Hao Wang et al.· Parkinsonism & Related Disor...· 0 citations
Parkinson's disease (PD) and multiple system atrophy (MSA) are alpha-synuclein-related neurodegenerative disorders with overlapping motor and non-motor symptoms but distinct pathology, clinical management, and prognosis. Early differential diagnosis, particularly between PD and the parkinsonian subtype of MSA (MSA-P),...
Dai-Chao Chen, Hua-Da Tang, Yan-Fei Pan et al.· NeuroImage: Clinical· 0 citations
Background Parkinson’s disease (PD) and multiple system atrophy (MSA) are clinically overlapping neurodegenerative disorders that present with a complex, heterogeneous burden of motor and non-motor symptoms. Resting-state EEG reveals that cortical alpha slowing is a hallmark of pathological aging, yet its specific pres...
Dai-Chao Chen, Hua-Da Tang, Yan-Fei Pan et al.· Frontiers in Aging Neuroscie...· 0 citations
It is suggested that PD is characterized by extensive disruption of cortical-cerebellar functional hierarchy, exceeding the relatively limited alterations observed in ET.
Qiang Liu, Ze-Zhong Zheng, Mo-Xuan Zhang et al.· Frontiers in Neurology· 0 citations
